Company Overview and News
2018-10-11 zacks - 1
JetBlue Airways Corporation (JBLU - Free Report) reported decent traffic figures for September 2018. Traffic (measured in revenue passenger miles or RPMs) improved 18.5% year over year to 3.9 billion. On a year-over-year basis, capacity (or available seat miles/ASMs) climbed 19.3% to 4.9 billion.
ARCB JBLU MATX NSC
For those looking to find strong Transportation stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Norfolk Southern (NSC - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Transportation peers, we might be able to answer that question.
2018-10-08 seekingalpha - 1
As part of my research into Lazard (LAZ) I looked at Lazard Global Listed Infrastructure Portfolio Institutional Shares (GLIFX). A very nice find. Often the first thing I do is to look through a fund's portfolio to see what they own. The table below show this fund's largest positions:
EIX SIZAY NG LAZ RDEIF REE NGGTF CSX FPRUF NGG NSC
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and Pfizer (PFE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HAWLN HD LMT CAT HAWLM HAWLL UTX HAWEL NSC HAWEN HAWEM COP AAPL MSFT HAWLI PFE RPM CIT
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Norfolk Southern (NSC - Free Report) , which belongs to the Zacks Transportation - Rail industry, could be a great candidate to consider.
Railroad fortunes are contingent on coal as revenues from the commodity contribute significantly to the respective companies’ top line. Despite President Donald Trump’s pro-coal stance, the industry does not seem to have revived much. U.S. coal production registered 180.8 million tons in the second quarter of 2018, down 3.7% sequentially and 3.4% year over year. This was reportedly the third straight quarter decline.
LMT CP CP UNP CSX UTX NSC
The quarter-end baby! We all look and wait for a big dividend income month and September usually never fails. The leaves are changing colors, the temperature is dropping and I have a sweatshirt on. Sitting here with a nice cup of joe and looking at the dividend income that flowed into my account. Blessed beyond belief everyone. Now let's grab that cup of coffee and see my September dividend income results!
LMT BLT D BHPBF DWDP NSC MAT ISBA MYBF BHP KHC BBL BHP BHPLF DAL MCD
Despite high operating expenses, shares of Golar LNG Limited (GLNG - Free Report) have fared well in a year’s time. The stock has gained 27.5%, against the industry’s decline of 6%.
ARCB GLNG TRN NSC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NSC / Norfolk Southern Corp. on message board site Silicon Investor.
as of ET